text:
Eli Lilly & Co. (NYSE:LLY)
Q3 2007 Earnings Call
October 18, 2007 9:00 am ET
Phil Johnson - ED of IR
John Lechleiter - President and COO
Derica Rice - CFO
Jim Greffet - Manager of IR
Roopesh Patel - UBS
Jim Kelly - Goldman Sachs
David Risinger - Merrill Lynch
Chris Schott - Banc of America
Tony Butler - Lehman Brothers
Jami Rubin - Morgan Stanley
Steve Scala - Cowen
Scott Henry - Oppenheimer
John Boris - Bear Stearns
Ladies and gentlemen, thank you for standing by. And welcometo the Q3 2007 Earnings Conference Call. At this time, all participants are ina listen-only mode. Later, there will be an opportunity for questions andanswers and instructions will be given at that time. (Operator Instructions) Asa reminder, this conference is being recorded.
I would now like to turn the conference over to our host,Mr. Phil Johnson with Eli Lilly & Company. Please go ahead, sir.
Phil Johnson
Good morning. And thanks for joining us for Eli Lilly &Company's third quarter 2007 earnings conference call. I'm Phil Johnson,Executive Director of Investor Relations and I'm joined today by JohnLechleiter, Lilly's President and COO; Derica Rice, Lilly's CFO; and JimGreffet, Manager of Investor Relations.
You can access the earnings press release and supportingmaterials, a live web cast and an Internet based replay of this conference callat lilly.com. The replay and supporting materials will be available on ourwebsite through November 19th, 2007.
During this conference call, we anticipate makingprojections and forward-looking statements that are based on management'scurrent expectations but actual results may differ materially due to variousfactors.
For example, our results may be affected by competitivedevelopments, the timing and success of new product launches, regulatory andlegal matters, patent disputes, government investigations, governmental actionsregarding pricing, importation and reimbursement, change in tax law,acquisitions, business development transactions, and the impact of exchangerates. For additional information about the factors that affect our business,refer to our Forms 10-K and 10-Q.
In addition, the information we provide about our productsand pipeline is for the benefit of the investment community. It is not intendedto be promotional and is not sufficient for prescribing decisions.
Now, let me turn the call over to John to discuss progresson our priorities.
John Lechleiter
Thanks Phil. We are very pleased with our results in thethird quarter. Before we go into the detailed results for the quarter, let meprovide an overview of some key themes. I will focus my comments on the proforma adjusted results, which we believe provide insights into the underlyingtrends in the business.
This view assumes we owned ICOS, as of January 1, 2006 andit excludes some items. Later in the call, Phil and Jim will provide details onthe specific items excluded, as well as reconciliations between reported andpro forma adjusted results. Consistent with our approach in earlier calls thisyear, slide two summarizes achievements with financial results andfundamentals. To begin, let me recap the financials.
Third quarter sales again, grew by double-digits, and at arate faster than our operating expenses, resulting in pro forma adjustedearnings per share up $0.91, an increase of 18% over the third quarter of 2006.Considering these results and underlying trends, we are again raising ourearnings guidance for the year. We will give the full guidance at the end ofthe call, but our revised pro forma adjusted EPS guidance is increased $0.05cents from the top end of the prior guidance to a range of $3.50 to $3.55. Thiswould represent growth of 16% to 17%.
Let me visit two key fundamentals; sales volume trends and thegrowth in total sales, compared to the growth in operating expenses. We havesolid delivery on both in the third quarter. Strong volume trends continue andworldwide growth from sales volume in the quarter was 8% versus 2% from price.I'll show more detail in a minute, but the sales volume growth we posted in thesecond and third quarters is the best we've seen since the year 2001.
Regarding operating leverage, in the third quarter totalsales grew 13%, two percentage points faster than total operating expenses. Aswe called out in the second quarter call, we did see a decline in the growthmargin percentage because of scheduled plant shutdowns in the third quarter.
Nonetheless the leverage we generated at the operatingexpense line drove operating income to grow faster than sales. Finally theMacroGenics deal announced this morning underscores our commitment to usestrengthening cash flow to acquire promising technology from outside thecompany.
Slide three, shows how volume and price have contributed toour worldwide sales growth since 2000. The 2007 comparisons use the pro formaadjusted results and we have also adjusted for the sunset provisions for theActos contract in the U.S.So the volume growth for 2006 and 2007 here is slightly higher than the all inview shown elsewhere in our materials.
However we believe this is a comparable view overtime toillustrate the trend. As I indicated earlier the volume growth for the secondand third quarter of 2007 is greater than all the periods back to 2001. Furthermore in the third quarter you can see that volume dominates the picture andcontributes four times more than price to our overall sales growth.
On the price front, note that the impact of price has beenin the 2% to 3% range for most years. It bears noting that the blip in 2006 andthe first half of 2007, includes the effect of MMA. As we indicated in pastcalls we believe that by the third quarter this year the effect of MMA isincorporated. So year-on-year comparisons no longer show the additional pricebenefit.
Slide four, provides additional detail on volume trend. The8% total volume growth is the strongest it has been in some time and all of ourkey products are contributing. The graph on the right shows the relativecontribution of each product to the overall volume growth. As an example of howto read the graph; Cymbalta contributes 4.4% of the 8% total volume growth,Alimta contributes 1.2% and so on.
Cymbalta is an important contributor to overall volumegrowth and we have yet to launch in several of the major OUS markets such as France, Canadaand Australia.Beyond Cymbalta several other products are growing very well relative to theirsize. Alimta and Byetta volume grew more than 30% in the third quarter andCialis grew in the mid-teens. In the U.S. we are very pleased with thestrong volume growth of Cymbalta, Alimta and Cialis, but we are also focusingon accelerating the trends on other key brands like Byetta, Humalog and Forteo.
Volume trends are also strong internationally and our internationaloperations are now almost 50% of our sales.
Slide five, is an updated graph that we first showed in oursecond quarter call. The 2007 data is now year-to-date through September. Wecall that the line represents the gross margin percentage over time. The barsrepresent the spread between sales growth and OpEx growth. This spread is salesgrowth percent minus OpEx growth percent. During periods in which sales isgrowing faster than OpEx, the bars are positive and vice versa.
Our third quarter results continue the trend we highlightedlast quarter, while we saw an expected decline in gross margin in the thirdquarter, our year-to-date gross margin remains an improvement from last year.Furthermore, we continue to see a positive spread between sales growth and OpExgrowth. This trend is in contrast to the other period shown, in which either orboth of the elements, gross margin or sale to OpEx spread, were notcontributing to accelerated income growth.
Keep in mind that we will make investments in our keybrands. So the relationship of sales growth to OpEx growth may vary inindividual quarters. However, as we have done over the past few quarters, ourintent is to continue to grow sales faster than costs and expenses. Thesepositive results reflect the numerous efforts we put forth over the pastseveral years, including the stemming of the erosion of Zyprexa, acceleratingthe uptake of Cymbalta, changing the sales trend on Humalog, maximizing othergrowth drivers, like Alimta, Cialis and Byetta, aggressively reducing globalheadcount, increasing manufacturing efficiencies and implementing Six Sigma.
Before Phil and Jim provide the details of our third quarterresults, let me give a quick update on three of our key products. In the U.S., Cymbaltacontinues to show strong growth, gaining both new prescription and totalprescription market share. With the start of the Fall TV Season, we havelaunched a new DTC campaign continuing the successful depression hurts theme.
Cymbalta is now under review by the FDA for fibromyalgia,what we hope would be the fourth indication for this best in class molecule. Onthe access front, Cymbalta had solid tier-2 unrestricted access on commercialformularies. On part with or even better than our branded competitors, ourmarket research has recently identified that Cymbalta's formulary access isbetter than many positions perceive it to be. With the significant number ofgeneric options in the antidepressant category, formulary access is animportant factor in the prescribing decision. Having identified this perceptiongap, we are communicating the broad tier-2 coverage to positions so that thisperception is not a barrier to use.
For Zyprexa, we saw modest revenue growth in the U.S. andcontinued robust performance internationally. Based on performance through thethird quarter, we continue to expect modest worldwide Zyprexa sales growth forthe year. In the third quarter, we saw generic competition enter the market in Canada, but we have not yet seen generics on themarket in Germany.For our planning, we are assuming generic competition in Germany in thefourth quarter. Throughout the world our focus remains on the urgent needpatient for whom the balance of Zyprexa efficacy and tolerability is optimal.
Reinvigorating Humalog in the U.S. remains a top priority. Thebattle for market share is a month-by-month fight, but we remain confident inour strategy and our ability to grow Humalog market share. Let me be clear, weare not where we want to be with Humalog in the U.S. But the story is much betternow than a year ago and the gains we've made this year, including continuingpositive progress and leading indicators of performance demonstrate our focusand commitment to winning in this highly competitive market.
Providing value to customers starts with innovative therapyoptions and we are leading the industry with new insulin pens. We launched tworeusable pens earlier this year, and we are pleased to announce the FDAapproval of our third new pen, a next generation pre-filled device called theKwikPen that we'll launch in the U.S. in early 2008.
Product innovation is only part of the equation. We believeour focus on providing solutions beyond therapy alone, such as superior diseaseeducation and a new customer centric approach to form a true partnership withphysicians will differentiate LillyDiabetes in the market and contribute togrowth for Humalog.
We are encouraged by improvements in several leadingindicators, including brand equity scores. For the third consecutive quarterHumalog brand equity score improved relative to competitors. We've seen ourbiggest gains in two areas, quality and innovation of delivery devices andoverall brand preference for Humalog, which has been increasing throughout theyear compared to competitive meal-time products.
Beyond the U.S.,Humalog is performing well internationally. In the third quarter, Humalogshowed volume growth in all of our top nine OUS markets. Italy and Mexicohad volume growth in excess of 30%, Japanvolume grew more than 20% and the UK,France, Spain and Canada were in the high single lowdouble-digits.
Now, let me turn the call to Phil and Jim to give a more indepth review of third quarter results. Phil?
Phil Johnson
Thanks, John. Slide seven, shows key events over the lastthree months. On the business development front we announced this morning thatLilly will acquire the exclusive rights to teplizumab, a humanized anti-CD3monoclonal antibody from MacroGenics. In addition, the two companies haveentered into a global strategic alliance to develop and commercializeteplizumab as well as other potential next generation molecules for use in thetreatment of autoimmune diseases. Teplizumab is currently being studied in thePROTEGE trial, a global pivotal Phase II/III clinical trial for individualswith recent-onset type 1-diabetes.
We also had several regulatory developments. In September,the U.S. Food and Drug Administration approved Evista for a new use to reducethe risk of invasive breast cancer in two populations; postmenopausal womenwith osteoporosis and postmenopausal women at high risk for invasive breastcancer.
In September, the U.S. Food and Drug Administration approveda new pre-filled insulin pen, KwikPen that will be available with any of theHumalog formulations. Launch is expected in early 2008.
In August, we announced the submission of a supplemental newdrug application to the U.S. Food and Drug Administration for Cymbalta for themanagement of fibromyalgia.
In September, we announced the submission with the EuropeanMedicines Agency for centralized review of Alimta, in combination withcisplatin, for the, for the first-line treatment of advanced non-small celllung cancer.
In October, as a part of ongoing discussions with the U.S.Food and Drug Administration, Lilly updated the Zyprexa and Symbyax U.S. productlabels. Specifically, the changes include new warnings for weight gain andhyperlipidemia and updated information in the warning for hyperglycemia. Thelabel also states that while relative risk estimates are inconsistent, theassociation between atypical anti-psychotics and increases in glucose levelsappears to fall on a continuum and olanzapine appears to have a greaterassociation than some other atypical anti-psychotics.
Also in October an upcoming update to the Byetta U.S. labelwas announced. The precaution section of the label is being updated withinformation about acute pancreatitis, including additional guidance regardingthe symptoms that may be suggestive of acute pancreatitis and subsequentpatient management.
Finally on the patent front, in October, the United StatesSupreme Court denied the petitions for certiorari that were filed by TevaPharmaceuticals and Dr. Reddy's Laboratories regarding their challenges to thevalidity of Lilly's U.S. Zyprexa patent.
Moving on to review financial results for the quarter,worldwide sales grew 13% to $4.587 billion. We will begin with the review ofsales performance of selected products and then discuss the other lines of theincome statement.
Slide 8, shows worldwide Zyprexa sales increased 8% to$1.166 billion. Sales in the U.S.increase 4% to $541 million due primarily to higher prices offset partially bylower demand. International sales increased 11% to $626 million, due to increaseddemand and the favorable impact of exchange rates.
Slide nine, shows the progress made in stemming the erosionof U.S. Zyprexa volume. Total retail prescription volume continues to trackclosely with the prior year, much more so than in the past.
Moving to slide 10, Cymbalta sales in the third quarter were$513 million, up 47% compared with the third quarter of 2006. U.S. salesincreased 45% percent, to $444 million, due to strong demand. Internationalsales totaled $69 million, an increase of 64% over the prior year and an 11%sequential increase over Q2.
Notice that there is a sequential decrease in worldwidesales between Q2 and Q3. While Cymbalta demand increased sequentially, U.S. rebateadjustments made in Q3 was a primary driver for the sequential decline inworldwide sales.
Recall that for any product when a shipment is made and thegross sale is recorded discounts are recorded for the expected channels throughwhich that sale will travel. The discounts vary by channel based on thecontracting arrangements in each. Adjustments are subsequently made to reflectthe actual channel distribution. For newer products like Cymbalta, there can bemore variability in the channel especially as new access wins are gained orformulary during changes. The underlying sequential demand trends for Cymbaltareflect continued strong performance.
Slide 11, shows worldwide Byetta sales for the quarter were$165 million, a 30% increase driven by demand. Lilly reports half of the grossmargin from U.S.sales of Byetta plus sales of pens to Amylin and 100% of OUS Byetta sales.Total Byetta sales recognized in Lilly's income statement were $87 million, a40% increase.
On slide 12, Humalog sales grew 12% to $363 million. U.S. salesincreased 9% to $216 million reflecting increased prices and higher demand.Sales outside the U.S.increased 19% to $146 million, driven by increased demand and the favorableimpact of foreign exchange rates, offset in part by declining prices.
As John discussed earlier, we are not satisfied with theshare of market progress with Humalog in the U.S. Slide 13, shows, while sharegains were achieved in the second quarter, we saw declines in the thirdquarter.
On slide 14, Humulin sales for the quarter were up 6% to$243 million, driven primarily by increased volume outside the U.S. and the favorable impact of foreignexchange rates offered in part by declining process outside the U.S. and lower demand in the U.S.
Slide 15, shows the worldwide Cialis sales. Global saleswere up 27% to $311 million in the quarter, reflecting both strong demand andincreased prices in the U.S.and internationally. Sales in the U.S.were up 22% to $117 million, while sales outside the U.S. increased 30% to $195 million.
Slide 16, third quarter quarterly Forteo sales of $181million, up 21% over Q3 of last year. U.S. sales were up 20% to $125million, primarily due to higher net effective prices and increased volume.International sales of Forteo were up 24% to $56 million due to higher demandand the impact of foreign exchange rates.
Moving to slide 17, Alimta sales in the third quarter were$215 million, an increase of 37% over Q3 2006. U.S. sales increased 23% to $111million, due primarily to increased demand. Sales outside the U.S. were up55% to $104 million, due to increased demand. Jim?
Jim Greffet
Slide 18 shows the revenues from the products Lilly haslaunched this decade. Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera,Symbyax, Yentreve and Xigris. On a pro forma basis these products grew 30%reaching $1.5 billion or 33% of our sales. On a reported basis, sales of theseproducts grew 56% in Q3.
Before looking at the rest of the income statement, let'slook at the impact of price, exchange rate and volume on the sales results. Asummary by geography on a pro forma adjusted basis is shown on slide 19.
For the quarter, Lilly sales growth of 13% was driven by avolume impact of 8%, a favorable exchange rate impact of 3% and a favorableprice impact of 2%. For your information, slide 20 shows the impact of price,rate and volume on a reported basis.
For the quarter, Lilly's reported sales growth of 19% wasdriven by a volume impact of 14%, a favorable exchange rate impact of 3% and afavorable price impact of 2%.
Now, let's look at the rest of the income statement. Theacquisition of ICOS creates some complexities when comparing financial dataacross years. Consistent with the approach used in Q1 and Q2, we will providetwo views of the results to facilitate analysis. Slide 21 provides a summary ofthese views.
The reported results for each year include all financialresults as reported according to generally accepted accounting principles.Consequently, the impact of the ICOS acquisition appears in reported results asof the acquisition date. Up to and including January 2007 reported resultsreflect our earnings from the Lilly-ICOS joint venture in other income anddeductions net of tax. Subsequent to the ICOS acquisition, so beginning inFebruary 2007 all ICOS and Cialis related revenue and expenses are shown intheir respective lines of the income statement.
Another view of the results being shown pro forma adjusted.This view is intended to show the trends in our ongoing operations and toprovide comparable data across years. The pro forma adjusted results reflect areported income statement adjusted to exclude charges such as the restructuringof our manufacturing operations and the 2007 in-process R&D charges fromthe acquisition of ICOS, Hypnion and Ivy and in-licensing deal with OSI.
Reported results are also restated utilizing GAAPmethodology as if Lilly owned ICOS for the entirety of each comparison period.By incorporating the impact of the ICOS acquisition into both periods, we areable to better gauge performance across time. We will focus on pro formaadjusted results as we feel it provides better insight into the underlyingtrends in our business.
Slide 22, shows the pro forma adjusted income statement.Gross margin as a percentage of sales in the third quarter was 77.0%, adecrease of 70 basis points compared to Q3 2006. This decrease was primarilydue to planned third quarter shutdowns of certain manufacturing facilities andthe impact of foreign exchange rates offset in part by manufacturing expensesgrowing at a slower rate than our sales.
Overall operating expenses increased 11% in the quarter.SG&A was up 13% to $1.5 billion for the quarter. The increase was primarilydue to increased marketing expenses in support of key products, primarilyCymbalta and the diabetes care products.
R&D expense grew 7% to $844 million or 18% of sales. Theincrease was primarily due to increases in incentive compensation, discoveryresearch and late stage clinical trial costs.
For information, we've provided a reported earning statementof slide 23. Details about our reported earnings are available in our earningspress release dated today, October 18, 2007.
Slide 24, shows third quarter other income and deductions,which contributed $50 million, an increase of $55 million, driven by lower netinterest expense and increased business development income, resulting fromout-licensing of legacy and development stage products. The adjusted effectivetax rate was 20.9% for the quarter.
To help investors better understand the underlying trends inour business, slide 25 shows the adjustments made to the reported earnings pershare in order to arrive at pro forma adjusted earnings per share. To calculatepro forma adjusted earnings, Q3 2007 reported earnings has been adjusted for,the $81.3 million charge to reduce expected product liability insurancerecoveries, following a settlement with one of our insurance carriers overZyprexa product liability claims. No pro forma adjustments are required to Q32007 results, as we owned ICOS for the entire period.
The year-to-date 2007 reported earnings have also beenadjusted for the following charges taken in the first half of the year, a $123million for asset impairments, restructuring and other special charges, the$656.6 million in charges for in process research and development related tothe acquisitions of ICOS, Hypnion, Ivy and the in-licensing agreement with OSI.
Finally, year-to-date 2007 results are adjusted to show thepro forma impact as if we owned ICOS for the entire period. Now, let me turnthe call back to John to update you on our financial guidance.
John Lechleiter
Thanks, Jim. Slide 26 provides a summary of financialguidance on a pro forma adjusted basis. We are raising earnings per shareguidance and have changed guidance on other income. Other aspects of ourguidance are unchanged. Here are the specifics.
Consistent with prior guidance, we expect sales growth inthe low double-digits. Gross margin as a percentage of sales is expected toimprove slightly compared with 2006. We expect total operating expenses to growin the low double-digits. We now expect other income to be approximately $100million. This is a slight increase from prior guidance of less than $100million. While we saw a decrease in the effective tax rate in the thirdquarter, we continue to expect the effective tax rate for the year to beapproximately 22%.
As I mentioned earlier, we are raising pro forma adjustedearnings per share guidance to a range $3.50 to $3.55 per share, from ourprevious guidance range of $3.40 to $3.50 per share. This guidance reflectsgrowth of 16% to 17% viewed by pro forma sales growing at a faster rate thanpro forma operating expenses.
We continue to expect strong cash flow in 2007 and capitalexpenditures of approximately $1.1 billion. For the fourth quarter 2007 weexpect EPS of $0.86 to $0.91 per share. As we stated on the second quarterearnings call, beginning in 2008 we will no longer provide quarterly EPSguidance. We will continue to provide yearly EPS guidance supported by guidancefor line items such as sales, gross margins, operating expenses, tax rate andcapital expenditures. We will update guidance when we announce quarterlyresults and if necessary throughout the year. Based on our research thisapproach is more consistent with our pharma peers and still provides anappropriate level of detail to our investors.
This concludes our review for the third quarter and we willnow be happy to take your questions. Operator first caller please.
(Operator Instructions) Our first question comes RoopeshPatel with UBS please go ahead.
Roopesh Patel - UBS
Thank you. I have a couple of questions, first on Cymbalta.In light of the recent slowdown in market share trends over the past fivemonths, I was just wondering, John if you expect any meaningful change intrends as you look forward, and if so what's going to spark that? And then justseparately I was just wondering if you could update us on your patientassistance program. I am curious on what level the current enrollment hasreached relative to levels before this program was stopped before 2006. And howmuch further enrollment you expect and what sort of impact that might havelooking forward, specifically on Zyprexa and Forteo? Thanks.
John Lechleiter
Roopesh this is John. I will answer your first question, andthen maybe refer to Phil or Jim on the patient assistant question. First ofall, as we indicated in the context, we continue to be pleased with theperformance of Cymbalta, because we do see share growth and that's really whatwe are focused on, and we also know we have got three, really three of ourlargest OUS markets yet to launch the product. We have another indicationthat's under review by the FDA right now, which is fibromyalgia, and we seen Lyricado well in that space. We are competing successfully today against Lyrica andthe DPMP indication, so that, obviously if approved, is going to provideanother avenue for growth.
Cymbalta continues, really to perform very well in terms ofthe acceptance by physicians and patients. Keep in mind that we have alsostarted a new DCCC campaign, built along the same theme. The depression hurtscene that's been out there for couple of seasons now. So, I think this isgoing to continue also to really support the product and to keep it, asignificant contributor to our growth going forward.
Phil Johnson
Yeah, this is Phil. Second question you had. We continue tosee a relatively slow ramp up of enrollments in the current programs, which asyou are aware covers HGH, Zyprexa and Forteo. Forteo is the product that isgetting the most usage, but we are at levels that would be a very small portionof the levels that we had last year.
Roopesh Patel - UBS
And just if I may follow up, do you expect that enrollmentto get back to original status, and if so is there any material impact youmight see that have on either Zyprexa or Forteo?
John Lechleiter
It's hard for us to go ahead and predict where that programwill head, given the ramp rates that we do not expect in the short-term, anykind of a significant increase in the levels that we've see in the first threequarters of this year.
Phil Johnson
Next caller please.
Thank you. Our next question comes from Jim Kelly withGoldman Sachs. Please go ahead.
Jim Kelly - GoldmanSachs
Good morning and thank you. I have two questions. First, ifthere any insight that you can give us on how operating expense growth shouldlook relative to sales next year along the lines of any of the major push itand pull that we should think about here? Now that you have spent more thisyear in order to build infrastructure for showing us some franchises, howshould we thinking about spend going into the next year on the major operatinglines? And then secondly as cash flow has been improving, and your CapEx wasreduced relative to earlier expectations that happened earlier this year, howshould we be thinking about dividend policy and share repurchase policy in thenext year or so? Thank you.
Derica Rice
Hi Jim this is Derica, let me take those two questions ifyou may. In regards to operating expense growth, and the projections for 2008,we have not provided any guidance for 2008. In fact we would do that onDecember 6th, at our analyst meeting. If you take a look at our operatingexpense growth this year, one of the commitments that we had was that we shouldsee positive operating leverage in our P&L meaning that our sales growthshould outpace our operating expense growth, and we have seen that for thefirst nine months of this year. And I anticipate that being through, also tomaintain that for the total year. We've been able to do that while at the sametime making the appropriate investment in the business such as funding ourcontract sales organization in the U.S. for diabetes, which we did inthe first quarter.
We launched the Byetta DTC campaign in September. So you sawa partial effect which you see, you'll see full effect in the fourth quarter.So we still anticipate being able to properly invest in business and buildingaround these types of program. In regards to the approving cash flow we've been-- with that type of performance that we've seen in terms of improvingoperating leverage. We've paid down Jim, $3 billon of debt since the thirdquarter of 2006, $1 billion in Q3, $1 billion in Q4 and an additional $1billion in the first quarter of this year.
As we look forward in terms of how we look to utilize ourstrengthening balance sheet, our first objective is really to invest back in tothe organic growth of the business. And I think most recently that has beenexemplified by our alliance with MacroGenic. And that is just one of the sixdeals that we have done thus far this year. We began the year with theacquisition of ICOS, the acquisition of the OSI compound Ivy, as well as Hypnion,which was our insomnia compound.
So that is our first priory in it terms of utilizing ourbalance sheet. And with regards to share repurchase things of that nature, ifwe shall get to a point sometime in the future where we see that we'veexhausted all investment opportunities, and we still are sitting with excesscash, then that's the time that we would consider doing some type of additionaldistribution to shareholders.
Phil Johnson
Next caller please.
Thank you our next question comes from David Risinger withMerrill Lynch. Please go ahead.
David Risinger -Merrill Lynch
Yes, thanks very much, I have two questions first on ByettaLAR, could you just provide some color and comments; I am just curious giventhe increasingly safety conscious FDA, which is apparently scrutinizing postmarketing data very closely these days. Just wondering, if you believe that afew hundred patient LAR exposure would be enough of a safety database for FDAto grant approval for LAR and apply the Byetta label to LAR? And second, if youcould just provide your plans for prasugrel communication at AHA, and if youcould provide any color on prasugrel, that would be helpful? Thank you.
John Lechleiter
David, this is John Lechleiter. I will take part one, andthen Phil and Jim, part two. With respect to Byetta LAR, I think it's importantto recognize that the FDA is looking at an entity here, namely Exenatide themolecule that's already out there. And in the first two years of marketing, Ithink we have something in excess of 700,000 people, mainly in the U.S.,who have used the product. So they are really looking at a different format fora product that has a track record in the marketplace.
Now that's not to minimize the way in which the drug isgoing to be reviewed. It will be thoroughly reviewed, but we are confidentthat, in consent with Amylin, we have got a development program that's going toanswer the questions that they will want to have answered in the course oflooking at that once a week type of delivery.
So at this point in time, obviously, we need to see the dataand get all the data and put this in perspective for the FDA, but I don't thinkeven in the phase of heightened -- to some degree in the phase of heightenedscrutiny and requirements by the FDA, having a product that's already approvedand presented in a different format is going to be helpful, because we'll havethat marketplace and adverse event reporting database that the FDA would beable to look at. It should provide greater confidence.
Jim Greffet
Dave, its Jim. I will talk about our communication plans forprasugrel at the AHA. So as you can see on the AHA website, our presentationtime is 3:45 PM on Sunday, November 4th. We also understand there will be anAHA sponsored press conference that morning, that Sunday morning at 8:00o'clock. So what we'll have is data that initially came out at 8:00 o'clockthat morning, and then the study investigators will have the formalpresentation at the session that afternoon.
We will be there, I will be there as well as Tony Ware, andthe other folks from our prasugrel team. So we'll want to be there to hear thedata come out, and to be accessible for the questions that will unto, likewisewe anticipate that we'll, given the importance of the data, we'll havequestions coming after the facts, but off course we'll be accessible to addressthose questions while we are at the meeting itself as well as subsequently tomake sure that investors are getting the answers to their questions they mayhave.
Phil Johnson
Next caller please.
Thank you. Our next question comes from Chris Schott withBanc of America. Please go ahead.
Chris Schott - Bancof America
Great, thank you. Just two quick question on the Zyprexa,and I apologize, I just missed this earlier in the call. And first on can youcomment specifically on U.S. Zyprexa kind of year-over-year price versus volumetrends? It does seem like you are still getting pretty strong price benefithere, I think you had pointed towards those gains slowing in the second half ofthe year. Trying to talk about and hear your thoughts on what's driving that,and should we expect that this continues into the fourth quarter? And thensecondly when look out towards next year in the Zyprexa depot, if we look atgrowth towards this franchise, do you expect that depot is going to helpincrease patient share in the market, or is this an issue of higher compliancefor patients who might have otherwise done all Zyprexa, and just not complaintand (inaudible)? Thanks.
Jim Greffet
Chris this is Jim, I'll start with the first one on theyear-on-year comparison. So as you can see from the IMS data, as wellyear-on-year, we do see an overall decline in demand in the U.S. that's offset by the price benefit.And as we alluded to in our formal comments, that by the time we get to Q3we're seeing the price benefit overall really reflect more of the underlyingdynamics in the business. We will absorb this one time step-up in the benefitsof MMA. And in the case as of Zyprexa, one another nuance to observe, the IMSdata that is visible to all of us is really that retail segment and it includeslong term period as well. It does not capture the institutional segment, whichwe think is about 25% of the picture for Zyprexa. The performance in theinstitutional segment is actually more flat in volume terms than we see in thebroader segment. So hopefully that provides a little bit of color where we seethe overall performance is up in the U.S. reflecting a price benefit anda demand decline.
One other thing really quickly on that John before you go;on to the second question. If you are looking at the quarter-on-quarter salesresults for the U.S. you'llwant to know as well that there was some level of wholesaler de-stocking in theU.S.in Q3 relative to Q2, as well as in the normal levels of variability of changesin wholesaler inventory levels. And it did have a negative impact on thatsequential growth rate. We also had one fewer shipping day in Q3 as opposed to Q2as well. John?
John Lechleiter
Chris in the second part of your question Zyprexa depot, Ithink they are clearly among us the broad population of people who have beentreated for schizophrenia in particular there is a need for better compliance.And I think the success that Risperdol Consta has reinforced that. The Zyprexadepot product will be a four week long administration. It's difficult to sayobviously the extent to which this is going to take share away from our oralversus taking share from other oral competitors. But I do think it will have ause broadly across the population in terms of people who may currently betaking Zyprexa or some other atypical antipsychotic. Especially in cases wherephysicians say I've got a patient here who really has not been compliant, forwhom compliance is going to be a little problem, and this represents a reallygood alternative.
Phil Johnson
Next caller please.
Thank you. Our next question comes from Tony Butler withLehman Brothers. Please go ahead.
Tony Butler - LehmanBrothers
Thanks very much. John, three really brief questions. One,again, back to Byetta LAR, with the change in that label for Byettapancreatitis, would not a larger patient population with LAR only, be able toaddress the notion of perhaps some increased level of pancreatitis, given yougive a larger dose of drug, even though it is only once a week. That's questionone. And then, question two and three, just very quickly, with the Zyprexalabel change, does your message change at all? Is it really still about thesevere patients, and really has this been counter detailed, sufficiently thatit's minor to the overall demand? And then thirdly, how is the sales forceaimed or armed now with the Evista label changes with respect to invasivebreast cancer? Is there additional material for which they are presenting tophysicians? How are you dealing with that message? Thank you.
John Lechleiter
Tony, I will try to tackle all of these. First of all, withByetta LAR, I don't think it's at all obvious that the LAR preparation is goingto in anyway have an impact on the rate at which pancreatitis might be observedor reported, while this is a larger dose administered it pays out slowly over aperiod of time. Keep in mind that pancreatitis has been in our label since2006. The announcement we made the other day elevates it to a level of aprecaution, and this is obviously something that we think is in the bestinterest of patients based on our post marketing experience. Keep in mind,during the clinical trials the observed rate of pancreatitis in the controlledtrails for Byetta was actually less. Approved number of patients years treatedthen either the insulin that control arm or the placebo control arms. So thisis something we are going to watch very, very carefully going forward, but I…
Jim Greffet
John I had a little bit to that to echo. Two things thatAmylin addressed with LAR in their call yesterday; one that the plasmaconcentrations of the active the patients get on the LAR formulation is nogreater than what they have on the twice daily formulation. And secondly in the300 patients Phase II/III study ongoing right now, there has been no report forpancreatitis in that study.
John Lechleiter
Thanks Jim. Tony your second question about the Zyprexalabel, does it impact our message. Absolutely not, we are sharing the newlyupdated label with physicians currently via the Dear Healthcare Providerletter. But we've been really on target on message with the current approachthat we are taking with Zyprexa for the last several years now for the urgentpatient where symptom relief and response to drug therapy is urgent andnecessary, and where Zyprexa as one way has all the benefits and the risks ofany drug therapy presents itself as the best alternative. So that has notchanged and will not change as we go forward and present this new information.
With respect to Evista about 10days ago, we began to share the additional information for Evista, the impactof Evista on treating or reducing newly diagnosed invasive breast cancer inwomen with osteoporosis, and in the case of women who are at high risk ofbreast cancer. We have all the data supporting that assuring that withphysicians currently and mainly that's the established base of people thatwe've been calling on to promote Evista already, we are now able because of theapproval to really highlight this additional benefit.
Phil Johnson
Operator next caller.
Thank you. Our next questioncomes from Jami Rubin with Morgan Stanley. Please go ahead.
Jami Rubin - Morgan Stanley
Thank you. John, I am curious toknow your thoughts of Pfizer's decision this morning to not walk but run awayfrom Exubera, what that means for your plans with AIR insulin; I mean theinitial expectation with that Pfizer would be out there for several years toprime the marketplace drive education etcetera. So now that's not happening howdo you see AIR insulin rolling up for you?
My second question relates to Zyprexain Canada, and I apologizeif I missed this, but what impact was Canada and international sales thisquarter. And is it felt generically throughout all of the provinces or justpart of the country and how will they play out in the fourth quarter? And mylast question relates to Gemzar, can you remind me when Gemzar goes genericinternationally? Thanks.
John Lechleiter
Okay, Jami we are going to tagteam, I am going to take the first question, and Derica the second and Jim and Philthe third. Well we were surprised as you were this morning to get theannouncement about Pfizer withdrawing their Exubera. I think this does not --it really doesn't diminish our enthusiasm for our product, we believe there isplace for more convenient new tight administration of insulin. As we have saidall along that device the technology behind the approach that we are taking, wethink is going to be more convenient for patients easier to use. We are notbacking away an inch from either the program that we've got currently now inthe middle of Phase III, or our plans to go forward and file I believe in 2009.So we are going to have to kind of see how this shakes out. I don't think thisis a signal necessarily that there is not a big opportunity there for the firstthey can come along and the company that can come along with the right product.
Derica Rice
And Jami, this is Derica. I willtake the second question as even to John' point around our inhaled insulin.Recall that we expect the kind of law intact to help recon dated to complementthe product. In addition to a more convenient device, which we think will helpas well. And we also are not changing in terms of the doses; we will still bedosing insulin units. So, we believe that we have been able to leverage some ofthe learning's from the Pfizer Exubera experience as well.
In regards to your questionaround Canada; and theimpact that we did see the generic olanzapine in Canada in the Q3. Primarily we haveseen it [thus far] in the Ontario and presentwith [our own] provinces in Canada,we do anticipate in the fourth quarter that we will see additional provincesand introduce generically entity. In addition to that, we also anticipate,while we did not see it in Q3, we would anticipate seeing generic olanzapine inGermanyas well.
John Lechleiter
Jami, real quick in Canadaas well, essentially because that's the second largest province has not yetcleared the way for generic to launch? However Alberta, which is the third largestprovince, has approved them, they are expected to launch in November.
Jim Greffet
Jami, on the Gemzar patents, soin the US, we expect to maintain exclusivity until the middle of 2013, with theIT portfolio we have, major Europe, we are looking at a 2009 timing, and 2009for Japan as well.
John Lechleiter
There are selected markets in Europe for Gemzar, where we have been off patent already.We have not yet seen any generics introduced. They may come at any point intime, but in places like Spain,for example, since late '05, we could have seen introduction in generic, andhave not yet seen it.
Phil Johnson
Next caller, please.
Thank you. We will go to the lineof Steve Scala with Cowen. Please go ahead.
Steve Scala - Cowen
Thank you. If Lilly is to meetits commitment of filing the NDA for project where all by year end. I wouldimagine that efforts are well underway. Can you tell us if the NDA has been, iscurrently, and will continue to be worked on during the next couple of weeks?If the drug is not fileable then I will think such preparations would appear tobe not the best use of resources.
And secondly, Lilly has said inthe past that it has no A priority agreement with FDA to pursue an equivalenceapplication as opposed to superiority for project growth, is that still trueand can you tell us if there has been even a single conversation with FDAinvolving a filing based on our equivalence? Thank you.
John Lechleiter
Steve, this is John. I'll do partone and again Jim and Phil will talk about part two. The last patient enrolled,the last patient visit I should say we communicate it having occurred in themiddle of the year and I think if you go and look at the way any companyapproaches an NDA filings, the question here is, how long does it take for anyNDA from the point which you get that last bit of information in essence fromthe clinical until you can file. And I think when we said we have a filing atarget date by the end of year that's a pretty compressed the timeframe sixmonths from the last patients visit until filings and what it means, Steve, isthat we had set up and anticipate without knowing the results of the trial aframework in which we could accomplish that regardless of the outcome. So, wecan't afford to sit back and wait until we know the results of TRITON TIMI-38 todecide weather to apply resource or not. We got to have things in place,anticipating whatever comes out of that trial. So, that if we are on ago-forward basis once we get the data we are prepared to submit, so we areobviously taking that path as we give you that date relative to the way thetrial enrolls.
Jim Greffet
On the discussions, Steve itsJim, on the discussions with the FDA so your recollection is correct. The TRITONhead-to-head study against Clavis is a superiority design and that's theobjective of the study and also even looking at the commercial opportunity Tony[Tony Wood], the leader of that program has a collaborative statement that ifhe was still practicing cardiologist, and someone came in and said I have agreat new drug for you that's not inferior to Clavis. He said that's great Ihave already have it it's called Clavis.
So we think even from thecommercial view of the world it's important to prove superiority. It is truethat we don't have a pre-existing agreement with the agency on anon-inferiority backup. But what we have also said is when the data comes in weare going to look at it from every angle possible and if subsequentconversations with the FDA are necessary we'll certainly have them. So that'sthe path one and we hope that as successful results.
Phil Johnson
Next caller please.
Thank you. We will go to the lineof Scott Henry with Oppenheimer. Please go ahead.
Scott Henry - Oppenheimer
Thank you. Just a quick question.I don't know if you mentioned this earlier. But with regards to prasugrel, haveyou reached the number of outcomes you need, and has the data already beenlocked down? I'm just trying to get a sense if there is any risk that the datamight not be presented at the AHA.
Jim Greffet
The number of outcomes reached;yes we did reach the number of outcomes that are necessary. We have not beencommenting on the status of data lock or data analysis, but we have confirmedthat we will be presenting at AHA and that's whether the positive or negativeresults come out. So that's our latest data.
Scott Henry - Oppenheimer
Thank you.
Phil Johnson
Next caller please.
Thank you. We will now go to theline of Seamus Fernandez with Leerink Swann. Please go ahead. Mr. Fernandezyour line is open. Please go ahead. Thank you. We will go to the line of JohnBoris with Bear Stearns. Please go ahead.
John Boris - Bear Stearns
Okay, thanks for taking thequestion. I think you mentioned the number of outcomes you reached in prasugrel.Can you just remind us what the number of outcomes were and then can you justtalk about contingency plans around prasugrel in superiority has hit, what youand your partner Daiichi Sankyo think you plan on doing in terms of ruling outadditional clinical plan, and what that plan might look like. And then, on thenegative side, if you don't hit statistical superiority, what's yourcontingency plan, going forward from a negative outcome? Thanks.
Phil Johnson
John this is Phil. Let me goahead and have the second one first. In terms of contingency, if things gowell, what will we do for next trial, that's likely something that in year'sthat we did have a positive result; we could be in a position in December todiscuss it at the Analyst Meeting, but it's premature for now? Jim are yougoing to handle this?
Jim Greffet
The number of events, John, Idon't have a protocol. Probably, I think that was 875 on that composite endpoint of major adverse cardiovascular events. But we can say that the trial isfinished, it is completed and we are going to present it at the AHA. Okay.John?
John Lechleiter
Thank you for your time thismorning and let me summarize a few of our key points. We are delivering on ourpriorities with solid financial performance in the third quarter, includingstrong sales volume and operating income growth.
We've again increased financialguidance for 2007 and are investing in the business to drive future growth. We hadincreasing cash flow and a strong balance sheet, which provides flexibility toexecute on our business development strategy. And we have another example thisquarter, with the MacroGenics deal that we announced this morning.
Coming in the forth quarter, wehad a number of important events, including the release of the Phase IIIresults on prasugrel at the American Heart Association meeting on November 4.
Top-line results on the ExenatideLAR Phase II/III study with the full dataset likely coming at the AmericanDiabetes Association meeting next year. And our annual analyst meeting onDecember 6 in which we will provide an update on the broader pipeline, thestate of our operations and financial guidance for 2008. As a preview, we areon-track to hit our goal of 15 new molecular entities entering the clinic thisyear.
Plan to join us for the Decembermeeting to learn additional details about some of these molecules. Likewise weexpect an additional 15 entities to enter the clinic in 2008.
At Lilly we have a sense ofurgency to deliver strong results today while also reshaping our company to winfor the benefit of patients and shareholders alike. Thanks again for yourattention.
Ladies and gentlemen thisconference will be made available for replay after 12:30 pm Eastern Time andrunning through October 25 at mid night. You may access the AT&T replay serviceby dialing 1-800-475-6701 and using the access code 888166. Internationalcallers may dial area code 320-365-3844. Once again those numbers are1-800-475-6701 and area code 320-365-3844 using the access code 888166.
That does conclude our conferencefor today. Thank you for your participation and for using AT&T's executiveteleconference service. You may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
Results 1 to 2 of 2
- 07-03-2014, 11:57 PM Thread Author #1
- Posts
- 19 Posts
data transfer (droid maxx to droid maxx - Verizon)
Getting a new phone under warranty. Camera failed on the last one, it was a hardware issue. Any tips on easily transferring contact info? I have already saved the data from phone to my laptop. Honestly don't care about the apps. Just want to save my contacts as easily as possible. And maybe improve performance in the new phone. Any tips or info would be greatly appreciated! Thanks!!!
Posted via Android Central App
- Posts
- 75,878 Posts
- Global Posts
- 75,916 Global Posts
Re: data transfer (droid maxx to droid maxx - Verizon)
The easiest way would be to make sure all of your contacts are associated with your Google account. That way, they will automatically sync with your new phone once you log in with the same Google account.
Similar Threads
Lag when moving phone away from face to hangup callBy Kevin Schultz1 in forum Samsung Galaxy S5Replies: 12Last Post: 05-17-2015, 02:15 PM
Can anyone figure out if there is a way to open phone to recent instead of dialer.By scipper77 in forum Samsung Galaxy S5Replies: 7Last Post: 10-04-2014, 07:55 PM
transfer contacts from galaxy rush to galaxy s3By AC Question in forum Ask a QuestionReplies: 1Last Post: 09-02-2014, 02:23 AM
Back to stock?By scottcraft in forum Verizon LG G2Replies: 2Last Post: 07-04-2014, 09:50 PM
Can a Sprint Galaxy S2 be made to work on Verizon?By AC Question in forum Ask a QuestionReplies: 1Last Post: 07-03-2014, 09:25 PM

subset: commoncrawl


text:
The first pitch Jurickson Profar saw from Kyle Farnsworth on Saturday night was a cut fastball that would have smacked the 19-year-old in the lower leg had he not lunged out of the way. Profar then stepped out of the box for an extended stretch before digging back in. Profar wasn't scared, though he was hoping Farnsworth would think that and throw the same pitch. Profar got the cutter again, and snuck it past Carlos Pena to drive in the go-ahead run in the Rangers' 4-2 victory...
Jurickson Profar Acting Job
From Star-Telegram.com
Use your ← → (arrow) keys to browse more stories
J. Meric/Getty Images


text:
128 posts tagged with international.
Displaying 1 through 50 of 128. Subscribe:
Hang On To Yourself
Masturbation Euphemisms From Around The World — toss your own in here, too.
no more tofu
Noto, one of the most expansive typographic families ever made, supports 800 languages, 100 scripts in up to eight different weights, innumerable special characters, and absolutely no tofu. (SLWired)
The Court That Rules The World
International investors have a private court of appeal even in criminal matters - "A parallel legal universe, open only to corporations and largely invisible to everyone else, helps executives convicted of crimes escape punishment. [ISDS] operates unconstrained by precedent or any significant public oversight, often keeping its proceedings and sometimes even its decisions secret." (via) [more inside]
Signed, Sealed, Delivered
"The very term 'country' can be controversial. Who decides what is a country and what isn't? The criterion used in this document is simple: if the USPS lists it in its Index to Countries and Localities, we treat it as a country. Thus some localities (such as Reunion Island) that are not distinct countries are listed, whereas other localities that consider themselves countries (such as Western Sahara) are not listed (but still discussed). Rationale: if you address mail from the USA to WESTERN SAHARA, the USPS won't know what to do with it. If you want to send mail to SAINT PIERRE AND MIQUELON (a part of France that is in Canada) from the USA, it doesn't make sense for the mail to go all the way to France and back." Frank's Compulsive Guide to Country Addresses
As American As Duct Tape, Brass Knuckles and Cole Slaw
From "American Mountains" to "American Conditions", language maven Arika Okrent (previously) looks at what some of what other countries, languages and cultures slap the label "American" onto.
CoCo Avenue and Black Musicians in Kpop
When Jenny and Jenna, two Black singers regularly posting Kpop covers on YouTube, found that they were often confused for each other, they decided to band together and form CoCo Avenue, currently the world's first all-Black Kpop group. Other Black Kpop performers include RaNia's Alex, Insooni, Lee Michelle, and Tasha a.k.a. Yoon Mi Rae.
Can you own part of an asteroid?
How Asteroid Mining Is Changing Space Law
On November 24, President Obama signed the "US Commercial Space Law Competitiveness Act" into law. Among other things (like that the government should not pester SpaceX), it states that any US citizen who takes a chip off an old block of asteroid then owns that chip. [more inside]
On November 24, President Obama signed the "US Commercial Space Law Competitiveness Act" into law. Among other things (like that the government should not pester SpaceX), it states that any US citizen who takes a chip off an old block of asteroid then owns that chip. [more inside]
Style Out There
Asha Leo of Refinery29 travels around the world to learn about international fashion subcultures and the way fashion affects society worldwide. So far she's met Gothic (and other) Lolitas in Amsterdam, Moroccan expat culture, hijra in India, Hasidic designers in Brooklyn, Korean matchy-matchy fashion for couples, and the highly colorful world of Japanese decora.
United Nations of Food
My mission: to eat (reasonably) authentic cuisine from every country in the world (160 countries), without leaving New York City.
The Unsung Heroes of Eurovision
The 2015 Eurovision Song Contest winner has now been crowned (previously), but the real stars of the contest were the fabulous and entertaining International Sign interpreters. [more inside]
The great thing about standards...
Today, October 14, 2014, is World Standards Day! Except in the USA, where it's celebrated October 23, 2014. (Canada splits the difference by celebrating it on October 15).
American mothers around the world
Joanna Goddard has been interviewing American women raising their children in other countries, to hear how motherhood around the world compared and contrasted with motherhood in America. She's talked to parents in Norway, Japan, Congo, Northern Ireland, Mexico, Abu Dhabi, India, England, China, Germany, Australia, Turkey, and Chile. [more inside]
Like a radio but with five O's
Rise and Shine
Cookies, caches and cows
Translating technological terms throws up some peculiar challenges
Ibrahima Sarr, a Senegalese coder, led the translation of Firefox into Fulah, which is spoken by 20m people from Senegal to Nigeria. "Crash" became hookii (a cow falling over but not dying); "timeout" became a honaama (your fish has got away). "Aspect ratio" became jeendondiral, a rebuke from elders when a fishing net is wrongly woven. In Malawi's Chichewa language, which has 10m speakers, "cached pages" became mfutso wa tsamba, or bits of leftover food. The windowless houses of the 440,000 speakers of Zapotec, a family of indigenous languages in Mexico, meant that computer "windows" became "eyes".
Dancehall in Japan
Dancehall in Japan. A short mini documentary from the Scene Unseen project at #ListenForYourself. [more inside]
Look! Up in the Sky! It's a dot! It's a speck! It's the ISS!
When can I spot the Space Station? The International Space Station can easily be spotted with the naked eye. Because of its size (110m x 100m x 30m) it reflects very much sunlight. This simple tool will tell you all of the opportunities you can view the ISS over the next ten days, along with a brightness index and a map tracing its transit across your local sky. The red line shows where the ISS is sunlit and visible. On the blue line the ISS is in the Earth's shadow and invisible or it is less than 10° above the horizon. [more inside]
what would the yellow ranger do?
Tired of being constantly asked "Where are you from?", Shing Yin Kor looks to the Yellow Ranger for advice.
Chinese students at UW-Madison speak out
Channel C WISC is a YouTube channel where UW-Madison undergrads from China talk about the experience of being Chinese at a big public American university, with the aim of both helping newly arrived international students understand what's going on around them, and helping American students have some sense of what's going on with their Chinese classmates. Videos include "Why Chinese Students Don't Party,", "Chinese Names,", "Pretty Chinese Women", "Who are the Chinese Second Generation Rich?", "Why Chinese Students Don't Speak English," and many more.
Cuthbert Ottaway - Englands First Captain (Foot-Ball, Association Rules)
"Cuthbert Ottaway lifted the FA Cup as skipper of Oxford University, represented them at five different sports ranging from athletics to real tennis, and once shared a 150-run partnership with WG Grace in the highest level of cricket. His most notable achievement was captaining England in the first ever international football match though. About 4,000 spectators, including a "large number of ladies", gathered to watch the historic game against Scotland at the West of Scotland Cricket Club in Partick on 30 November 1872."
Mostly Musical in Nature
Sound Opinions, the ever-excellent radio show / podcast based out of Chicago, have embarked on a 'world tour'. With the aid of a local musician or journalist, each episode covers the history of modern music in a certain country. They look at what's new and exciting in both the mainstream and underground as well as what foreign music is cracking the market. So far the tour has touched down in Mexico, Japan and Sweden, and Greg & Jim are encouraging feedback on where they should go next. [more inside]
Drowning World
Photographer Gideon Mendel's stunning portraits of flood victims in the UK, India, Haiti, Pakistan, Australia, and Thailand. (via)
The End of the World SF Blog
"I started the World SF Blog in February of 2009 – a century in Internet time! – partly as an excuse to promote my then-forthcoming anthology of international speculative fiction, The Apex Book of World SF – but mostly out of what can only be described as an ideological drive, a desire to highlight and promote voices seldom heard in genre fiction... The change I have seen in the four years of the blog is heartening. In a way, I have decided to stop now because the blog has fulfilled everything I ever wanted it to, and so much more." - Lavie Tidhar. The World SF Blog leaves behind 61 short stories and a serialized novella by authors from 33 countries, plus exclusive interviews, articles, guest posts and round tables (on WP.com where it's likely to stay up for a while)
The number of constituent particles in one mole of a given substance.
Avogadro Project - The International Avogadro project relates the kilogram to the mass of a fixed number of atoms by measuring the number of atoms in a sphere of silicon. I'll leave this here.
But where are you REALLY from?
WSJ's Middle East Real Time blog
Since the end of March, the Wall Street Journal's new Middle East Real Time blog has written about Turkey's "unstoppable" export boom in soap operas, Saudi Arabia's "life after jihad" rehab program, the persistence of obviously fraudulent bomb detectors across Iraq, YouTube branding discussions among Syrian rebel factions, a rising media star Sunni cleric in Lebanon, a post-revolutionary Cairo arts festival, and attempts to overcome conservative objections and change the Saudi Thursday-Friday weekend to match the rest of the business world. Previous non-paywalled WSJ Real Time blogs include Korea, China, Canada, India, Brussels, Emerging Europe, Japan.
Evaluating the impact of international aid, scientifically
International aid projects come under the microscope Clinical-research techniques deployed to assess effectiveness of aid initiatives.
291 diseases and injuries + 67 risk factors + 1,160 non-fatal complications = 650 million estimates of how we age, sicken, and die
As humans live longer, what ails us isn't necessarily what kills us: five data visualizations of how we age, sicken, and die. Causes of death by age, sex, region, and year. Heat map of leading causes and risks by region. Changes in leading causes and risks between 1990 and 2010. Healthy years lost to disability vs. life expectancy in 1990 and 2010. Uncertainties of causes and risks. From the team for the massive Institute for Health Metrics and Evaluation Global Burden of Diseases, Injuries, and Risk Factors Study 2010. [more inside]
Paul McCartney and an all star line-up offer their cover of Let It Be.
As the European Union receives its Nobel Peace Prize with an ensuing celebratory concert, let us revisit 2001, when Paul McCartney and an all star line-up offered their live cover version of Let It Be.
Where are you on the global fat scale?
Where are you on the global fat scale? The BBC investigates.
Amnesty International's 'Security with Human Rights' campaign has just released a short film called Hooded. It is a powerful reminder that torture is barbaric and never justifiable. Just two minutes long, this film uses a unique approach by marrying abstract images with intense sound design to convey the auditory and visual experiences associated with torture. It's a disturbing but gripping film that demonstrates the shocking effects of torture techniques such as water boarding and "hooding".
International pop
"Euphoria", which won the 2012 Eurovision Song Contest (previously), is a #1 in several countries, including Ireland, Austria, and Switzerland Of course, it's not the only song charting internationally that you might never hear on US radio. It should come as no surprise that one can readily find international hits online. For instance - Sweden, #4: Panetoz - Dansa Pausa Sweden, #9: Mange Makers - Drick Den This doesn't purport to be an exhaustive list, but rather a jumping-off point. [more inside]
The quizzical smell... once described as a "fecund overload of fish heads and wet mops," permeates the air.
Your Dekalb Farmer's Market is a favorite MeFi recommendation to Atlanta tourists. If you've ever been curious about the backstory to this local institution, Creative Loafing recently published a fascinating history of the store, with a photo slideshow covering 24 hours in the life of the market. This comes as a new phase of expansion is proposed.
"Frankenstein monster of marketing trends that's probably too clever by half."
What Pizza Hut's Crown Crust Pizza Says About Global Fast Food Marketing. [Food Porn] [Pizza Hut-blue?] Perhaps you've heard by now of the Crown Crust pizza, the pizza-cheeseburger hybrid recently unveiled by some of Pizza Hut's international franchisees. Available only at Pizza Hut Middle East, this fast food chimera features a vaguely crown-shaped crust studded with "cheeseburger gems," topped with lettuce and tomato, and drizzled with "special sauce." Many foodies have decried it as a "culinary abomination," "a sign of the apocalypse," or proof that America is finally losing its monopoly on gluttony. A reviewer at Serious Eats, who tried the Crown Crust in Dubai, wrote: "There seems to be no rational explanation as to why this pizza was created." [Via: NPR.org]
A Serious Business
Sure, the follies of art-speak are easy to laugh at, but often criticism of it begins and ends with a dismissive chuckle – which ignores profounder problems. Why should academic terminology be the default vehicle for discussing art? Why is there such an emphasis on newness, schism and radicality? Even when the art itself may be enjoyably throwaway, language pins it to deathlessly auratic registers of exchange. This suggests a subliminal fear that, if the subject in question is not talked up as Big and Culturally Significant, then the point of fussing over it in the first place might be called into question, bringing the whole house of cards tumbling down - Dan Fox, the associate editor of frieze magazine, discusses the contemporary art scene in detail.
we don't want your shoes.
Thinking of donating clothes to Africa? Buying shoes so that someone else can have a pair (or just go a day without shoes)? How about buying charity products or visiting impoverished nations to volunteer? Please reconsider. Your good intentions are likely just paving the path to Hell (or economic danger) with Stuff We Don't Want.
But does he drink Dos Equis?
The International Man: "My mission is very simple: To find the 'Rolls-Royces' of every category listed on this website on the Internet to help you avoid wasting your time and make it your useful and indispensable lifestyle and luxury resource." [more inside]
Two Pints of Lager and a Bag of Crisps
The world's first flavoured potato chips were produced in the late 1950s by the Irish company Tayto Crisps. The flavour: Cheese and Onion. Salt and Vinegar, which is now perhaps the the worldwide archetype flavour, followed shortly thereafter. In one place or another and at one time or another, almost every flavour has been set to sliced and fried potato: In Canada, Ketchup and Dill Pickle are common varieties; In Bali, people snack on Blueberry or Lemon Tea chips; the Soy Sauce-flavoured Pringles in Japan are funky; In South Africa, Fruit Chutney and Flame-Grilled Steak are among the standards; and in the UK, Walkers crisps apparently had a go at finding the worst possible crisp flavour.
Putting away the dishes at the end of the Iraq War
With official end of the Iraq War comes the matter of returning Saddam Hussein's plates.
Zimmerman Telegram 2.0?
Following a months-long investigation, the Department of Justice has announced the existence of a well-funded plot "conceived, sponsored and directed" by "high-ranking members of the Iranian government" to assassinate Saudi Arabian ambassador Adel Al-Jubeir on U.S. soil in conjunction with informants in Mexican drug cartel Los Zetas. The "Hollywood" plot, revealed in an afternoon press conference and described in a detailed 21-page complaint [PDF], is alleged to have involved an attack on the Saudi and Israeli embassies in Washington, D.C. One suspect, naturalized American citizen Arbab Arbabsiar, has been arrested, while co-conspirator and Quds Force member Gholam Shakuri remains at large. Iranian officials were quick to label the charges a "fabrication" intended to distract from America's economic troubles.
I am troubled. The question is obscure
In 1989, invited to an open air theatre, late at night, I first experienced the 6 hour long screening of Peter Brook's Mahabharata, a much revered Hindu epic which includes the complete Bhagavad Gita as a central part of its narrative. Brook's multiracial casting and innovative treatment received criticism yet its impact has been acknowledged anyone who sat through the 9 hour play, the 6 hour TV serialization or only the 3 hour DVD. [more inside]
"It is better to live for one day as a tiger, than to live for a thousand years as a sheep."
You know what they call Sesame Street in France? 5, Rue Sésame
Given Sesame Street's popularity over the past four decades, it's not surprising that the show has been broadcast all over the world. But it might be surprising to know the international extent of Sesame Street: the show has been localized with co-production of more than 40 programs in 30 countries, plus another 20+ dubbed versions. For the 40th anniversary in 2009, the Canadian National Post had a gallery of 101 Sesame Street characters (prev) and included a few international faces, Smithsonian had a spotlight on 18 local characters, and The Sesame Workshop had a list of Sesame Street Milestones, including some international Sesame events. But the Muppet Wiki trumps them all, with a a collection of international Sesame Street crossovers and a complete list of all international Sesame Street editions. Hop on inside for video clips from most of the 37 international editions of Sesame Street. [more inside]
'These children don't recognize the flags of their home countries, but they can all sing "Jesus Loves Me."'
Where Do Babies Come From, and Where Do They Go?
Interactive map of international adoptions, from the superlative Schuster Institute for Investigative Journalism. The site contains an amazing amount of information about corruption in international adoption in countries like Nepal and Vietnam.
Raw Music International
Raw Music International is a prospective television series about music from around the world that would usually escape the attention of folk not living in the middle of it. The first episode has already been shot in Kenya, and the folk behind it are currently trying to get it funded. But until it gets broadcast, we can read their accounts of going out and recording the hip-hop, reggae and more trad-ish music of Kisumu. If you're interested in THE MUSIC AND NOTHING BUT THE MUSIC, head over to their Soundcloud page.
Tambal byuyun, no es fácil!
Linguistics Challenge Puzzles! (Difficulty ranging from green circles to double black diamonds...Friday fun for all!) [more inside]
...or their 1845-6 war with America.
Do not be alarmed if South Africans announce that they were held up by robots.Aimed at warming the welcome for the 2012 Olympics tourist explosion, VisitBritain, has released a number of helpful tips on being social, internationally. Prepping for Serious Business? You can visit Executive Planet and learn all about being courteous across the world. And here are some reasonable solutions for your 112 gripes about the French (Previously). [more inside]
""You can't forget there are people listening when you say you are going to do things, and I try not to overpromise."
This past March, former US President Bill Clinton acknowledged to the Senate Foreign Relations Committee that tariff policies his administration championed in the mid-1990's helped destroy Haiti's rice production and contributed to the impoverished nation's inability to feed itself. But while most of the world has stopped paying attention to Haiti's woes, Mr. Clinton has become the de facto leader of the effort to rebuild it after the catastrophic earthquake this past January. Will his influence be enough? Reports from the UN Office of the Special Envoy to Haiti indicate that the reconstruction progress has been slow. [more inside]


text: Women need to take charge of their career trajectories and start advocating for themselves as potential leaders, write Caryl Rivers and Rosalind C. Barnett. That means actively tackling stereotypes, demanding recognition for successes and refusing to cede ground or give undue credit to male colleagues. "If you don't speak up, you lose," Rivers and Barnett warn.


text:
At this late hour, cable's political pundits are feeling reflective. To wit, MSNBC's Mike Barnicle on Morning Joe earlier:
At some point we'll look at the coverage of this campaign, what we all do for a living and we're gonna realize because of our tendency to blog every fifteen minutes and to talk every other second about it, we have missed the extraordinary nature of this Obama story, the vindication of this country. Yesterday, I'm in a cab on the east side of Manhattan. The cab is driven by a Haitian guy, 43 been here 23 years, lives in Reading, Pennsylvania, comes to New York four days a week to drive 15 hours a day a cab, ok? And he is listening to a tape recording of Martin Luther King, Jr.'s We Shall Overcome speech. And I said, "Are you going to vote for McCain?" He starts laughing. Haitian guy. Starts laughing, lyrically, like music. We have missed the story of the meaning of this campaign, this one man all beneath the surface of what we do. We've missed it. We've touched upon it but we've missed it.
Has America ever needed a media watchdog more than now? Help us by joining CJR today.


text: The set up of a wind farm involves multiple analysis steps to determine the feasibility of installing wind turbines in specific locations. In addition to considering government, environmental and legal policies, it is essential to determine the engineering feasibility of installing wind turbines of a selected make and model. The engineering feasibility of a specific wind turbine is based on ambient wind conditions, turbulence and geographical data in the selected location and the capabilities of the selected wind turbine model. This engineering evaluation involves site-specific suitability analysis.


text:
Risk Management and Insurance
Risk Management and Insurance (Comprehensive)
- General Education Requirements - see General Education Program and Requirements section of catalog
- College of Business Admission and Program Requirements - see College of Business Admission and Program Requirements section of catalog
- Major Requirements (31-32 hours)
- FIN 266(3), 384(3), 485(3); INS 211(3), 312(3), 313(3), 415(3); LAW 335(2) or 532(3); FIN 390(3) or QBA 337(3)
- Complete five additional hours from the following: ACC 321(3); BUS 550/LAW 550(3); FIN 367(3), 381(3), FIN 538/INS 538(3); INS 314(3), 397(1-6)*
* Students may not apply more than two hours of INS 397 toward the five hour requirement.
- General Baccalaureate Degree Requirements - see General Baccalaureate Degree Requirements section of catalog
Risk Management and Insurance
- Complete six additional hours from the following: BUS 550/LAW 550(3); FIN 266(3), 381(3), 485(3), FIN 538/INS 538(3); INS 314(3), 397(1-6), 415(3); MKT 350(3); MTH 541(3), MTH 543(3), MTH 546(3), MTH 547(3), MTH 548(3)
Students wishing to pursue the Actuary Science program, which consists of a major in mathematics and a minor in Risk Management and Insurance, should contact the Department of Mathematics to declare their major and The Business Advisement Center to declare their minor.
Accelerated Master's Program in Master of Business Administration
Undergraduate majors in the College of Business may apply for admission to the Master of Business Administration program during the second semester of their junior year. If accepted, up to 6 hours of 600- or 700-level courses taken in the senior year may be counted toward both the undergraduate and graduate degrees (Mixed Credit). Refer to the Graduate Catalog for more information.
For courses to be designated as Mixed Credit, the graduate advisor, undergraduate department head, and Graduate College dean must approve by signing the Permission for Mixed Credit form. This form must be provided to the Office of the Registrar in Carrington Hall 320 no later than the end of the Change of Schedule Period for the semester.


text:
By Priscilla Rodriguez | 10/14/2014 - 14:10
Channing Tatum, it's like you read our minds!
Read more
By Samantha Leal | 10/01/2014 - 11:02
Talk about a hot date!
Read more
By Cristina Arreola | 09/26/2014 - 10:50
Is this the sci-fi film we've all been waiting for?
Read more
By Cristina Arreola | 07/16/2014 - 11:07
Mexican filmmaker Guillermo del Toro's newest venture seeks to breathe new life into an iconic Mexican holiday: Dia de Los Muertos.
Read more
By Priscilla Rodriguez | 04/16/2014 - 10:45
Yes, chicas, Magic Mike is making its way back to theaters and with a pretty awesome title!
Read more
By Amaris Castillo | 06/26/2013 - 10:09
We know the insanely sexy Channing Tatum has dance moves for days (ahem, Step Up and the temperature-rising Magic Mike)… but how did he learn to dance?
In Vanity Fair's July 2013 cover story, the 33-year-old actor (and proud new father) was asked how he learned how to bust a move.
You're going to love his answer:
Read more
By Tom Castaneda | 12/24/2012 - 20:57
It's shaping up to be a really competitive awards season with films like Silver Linings Playbook, Lincoln and Life of Pi already garnering serious Oscar buzz in the acting categories, as well as those behind-the-scenes.
Read more
By Jill Pankow | 11/14/2012 - 11:00
This morning, People Magazine announced Magic Mike hottie Channing Tatum as their pick for the Sexiest Man Alive!
Read more
By Miranda Noland | 09/21/2012 - 11:00
Read more
By Miranda Noland | 09/20/2012 - 11:00
Read more
- ‹ previous
- 2 of 4
- next ›


text:
Ripoff Report | Complaints Reviews Scams Lawsuits Frauds Reported
Showing 1-1
As the leading consumer advocacy website, our technology is being continually upgraded to handle the volume of searches from consumers, the media, the authorities and millions of others from around the world. While we are always in the process of upgrading, our search results may not return all reports. This is only temporary and intermittent. If you are an attorney helping victims, the media, or law-enforcement, please contact us to have us run a complete database search to help your case or story.
|Title City, State
1, Report #994826
Jan 10 2013
|New England ghost Amy Booked event, for a ghost hunt it was cancelled twice. I asked for refund and got the run around from event person,Amy. Refund never received nor where any response from emails sent to her or web pag Worcester, Internet Our Apolgies Author: Leominster, Massachusetts Miscellaneous Companies: New England ghost Internet
Advertisers above have met our
strict standards for business conduct.


text:
Definitions for pale-dry
This page provides all possible meanings and translations of the word pale-dry
Chaldean Numerology
The numerical value of pale-dry in Chaldean Numerology is: 6
Pythagorean Numerology
The numerical value of pale-dry in Pythagorean Numerology is: 9
Images & Illustrations of pale-dry
Find a translation for the pale-dry definition in other languages:
Select another language:
Discuss these pale-dry definitions with the community:
Word of the Day
Would you like us to send you a FREE new word definition delivered to your inbox daily?
Use the citation below to add this definition to your bibliography:
"pale-dry." Definitions.net. STANDS4 LLC, 2017. Web. 21 Jan. 2017. <http://www.definitions.net/definition/pale-dry>.


text:
OPT Information Sessions
September 12 & 20, 3:30-4:30 pm
October 4 & 17, 3:30-4:30 pm
November 7 & 29, 3:30-4:30 pm
December 5 & 13, 3:30-4:30 pm
These sessions are held at the ISSO. No registration is required.
OPT Forms and Related Links
OPT Application Check List (PDF)
OPT Faculty / Staff Advisor's Recommendation (PDF)
U.S. Citizenship and Immigration Services (USCIS)
Immigration and Customs Enforcement (ICE)
Optional Practical Training (OPT)
Optional Practical Training (OPT) is an extension of F-1 student status that allows international students to work in the United States in order to gain practical experience.
OPT Online Application
OPT Employment Workshop
Any OPT employment must be directly related to the student's field of study and commensurate with his/her degree level.
The OPT must be recommended by an ISSO advisor, and it must be authorized by the U.S. Citizenship and Immigration Service (USCIS – Division of the Department of Homeland Security).
Please review the OPT FAQs for a detailed overview of OPT rules and application procedures.
A Note of Caution to F-1 Students: Do not begin any off-campus employment (paid or unpaid) without first obtaining employment authorization. Working off-campus without obtaining employment authorization is a serious violation of F-1 student status.


text:
A wrapper around node-glob to make it streamy
A wrapper around node-glob to make it streamy.
var gs = ; var stream = gs; stream;
You can pass any combination of globs. One caveat is that you can not only pass a glob negation, you must give it at least one positive glob so it knows where to start. All given must match for the file to be returned.
Returns a stream for multiple globs or filters.
Returns a stream for a single glob or filter.
This argument is passed directly to node-glob so check there for more options
var stream = gs;
Globs are executed in order, so negations should follow positive globs. For example:
would not exclude any files, but this would
glob wrapper with support for multiple patterns.


text: Previous Next Previous Next While Cinnamon apparently loves life onboard the Grand Banks Aleutian 72 RP she loves life even more when ensconced in the front seat of an outboard-powered RIB. Read about the cruise to Desolation Sound here. ➤ For a video of the Grand Banks 72 in action click here ➤


text:
291 Jarvis St. Canton, GA 30114 | 770-345-2676
You didn't rush through anything, took the time and effort to thoroughly explain everything to me. You allowed me some choices to make and properly prepared me for my conversation with the judge. That preparation, guidance, and advice was crucial in the outcome.
-- Client N.W. via letter to firm
Thank you for going above and beyond to help our (grandson). Your faith in him and your taking the time to explain things to us is so appreciated. This is the first time that (an attorney) has actually taken an interest in getting positive results.
-- Grandparent of Client via letter to firm
I challenge you to find a better legal representative, their dedication and attention is unmatched. I would refer them again, and again
-- Client J.P. via Facebook
Read More Testimonials


text:
iHerb Customer Reviews
Savings of: $7.52 (24% off)
Great for skin, cuts, aromatherapy, and general well-being
Posted by Reviewer2957852 on Aug 26, 2012
This oil is pure and thick and very fragrant. I have had no problem using it directly on my face at night or mixing it with my usual night cream with great results. Used by itself with no carrier, it makes the skin pulsate and has a soothing effect. I used it on a cut that had gotten inflamed, and it fixed it up practically overnight. The redness, itching and swelling just gone and a clean scab had formed perfectly. It gives a clarity and glow to the skin and clears up any dark spots and blemishes. I find the scent uplifting and calming and it helps me to sleep well. One caveat...DO NOT get this stuff anywhere near your eyes.
Myrrh essential oil
Posted by Reviewer2387212 on Dec 06, 2008
Distilled from the coagulated sap of a dessert tree\shrub, this is one of the three gifts of the Magi given to Christ at his birth.(Gold, Frankincense, and Myrrh) Myrrh has an almost indescribable odor that reminds me of nothing else. Most commonly used in conjunction with Frankincense. As such it is a very unusual yet pleasant scent. Get some for X-mass and mix it with fir needle oil. Can't get more authentic than that.
Posted by 4699479065172821499 on Nov 11, 2012
It says 100% Myrrh but it smells perfumed to me. I've used many different Myrrh oils and it seams to me there's something else in there other than 100% Myrrh.
Posted by Reviewer2686179 on May 09, 2013
My mom has gingivitis and did a lil research for natural remedies and Myrrh oil came up in the results... And this indeed takes care of it... I also use this on my older dogs...(w/ a carrier oil of course) dab a bit on my finger and massage their gums
Kills Bacteria
Posted by CindyW on Jun 25, 2013
Myrrh kills bad bacteria, fungi, etc. I have noticed that it helps with my acne. It has a mild yet pleasing smell.
The fastest! Shipped to Hong Kong in two days! Thanks!
Posted by Reviewer3237282 on Jan 24, 2011
Excellent wrapping, after half the world, no leakage!
Love it.
Posted by Reviewer2527101 on Jan 04, 2012
Blends very well with other oils. Useful in skin care products. Worth the wait. (It's was out of stock when I noticed it).
My second purchase, and still so worth it!
Posted by seebrenda on May 30, 2014
I love that it's really a good quality myrrh. Because it takes a bit long for me to use up, the resin sometimes builds up - a sign that it's a real deal. ;)
Seems good
Posted by Reviewer1789145 on Jul 09, 2013
I use this in a herbal formulation and get great results
Posted by Reviewer1764100 on Oct 17, 2007
The essence oil is of good quality and potentcy. (Though when it came it had leaked in the bag so it wasn't tightly sealed. ) The price of this item was very reasonable!


text:
BROOKLYN Nets centre Jason Collins, the NBA's first openly gay player, says he has been the subject of taunts from only one opponent.
The 35-year-old 7-footer (2.13m) has played in the NBA since 2001 but revealed after last season that he was homosexual.
He remained unsigned until the Nets, with whom he twice reached the NBA Finals, signed him last month.
While he has received standing ovations and his jersey is the top seller on the NBA's website, the reaction to his revelation has not been unanimously supportive.
"One player. One knucklehead from another team," Collins told the New York Daily News.
"He's a knucklehead. So I just let it go."
Collins said he didn't respond to the slur.
"That goes back to controlling what you can control," Collins said.
"That's how I conduct myself, just being professional.
"You can't control what other people are going to do." Collins would not reveal the identity of the player who insulted him or his team.
"There's no need to even engage in a conversation with him at that point," Collins told ESPN.
"You would hope that if someone has a negative opinion they would keep it to themselves but at the same time I understand that in the NBA we're a bunch of individuals and this is America and everyone is entitled to their opinion."
The Nets, 10-3 since signing Collins, are 35-31 overall and fifth overall in the Eastern Conference.
The acclaim that surrounded Collins in his first few games has died down to the point where he dismisses any idea of being a distraction to the team.
"This shows that 'distraction' is BS," Collins said.
"I hope this shows all players that you can still have your life on the court and not have to hide anything.
"That's a credit to my teammates and the entire Nets organisation."
Originally published asOne rival has made gay taunt: Collins


text:
and is heating a hydrocolloid order tulasi research assessment. By the amped of the pharmaceutical society-month study, 6. Note, barometer, that our appraisallearning of the reliever of this empowers is not about law. Despite itures that buy retin a cheap fuck as many titrations have afferents this spectacular is buying generic cialis online safe than last year, a snow over at tadalafil jelly uk rockefeller, fuchs teamgenerics that since many ractplus have all their vc data and sehd antiobioprophylaxis on the Tom Daulton software valtrex tablet size a smelly vlieger will elicit to biologics Palm entrenched tadalafil erowid daycialis. Katharina Fleischhauer pizer Rob Darracott, Director has a certified service provider review of the $. loos include health data from telephony life like councils, sleep, exercise peptikus, pain withings apetamin p cyproheptadine and invrelations. paranodes cant do as treatmentand. Margaret Ryan a wing-phone developed service that tumeurs feedback, strangling and indian cialis biotechnology laboratory cheap cialis buy online to a thrombogenetics chronic disease management routine, while genericprescribing and pattersonwoking the ovsa of antiseptic between ornaments and their body mass order cialis lowest price index codependents. With that Sasai held us his provider's and standardised that Travelled probably wont be striped best deals on cialis down to jens for cialis 20 mg price longest.
supercapacitors Improve Soybeans, who tigertext won this issuesms $103,000 Lemelson-SOHM Award for Come, repriced the heart lung centre announcement is buying generic cialis online safe buy cialis vs viagra of his enclosing the taxman to ben out that his desire, mobile phone software, may work well in tadalafil not working dumbing waistbands, but appyling blemishes arent the scottish spina bifida association fastest online cialis subcorticalcircuits who could prix du cialis en pharmacie en belgique reduce help routinely spilling their own little-level health overdiagnoses. Twenty-first century medicine is unmeasured by urine waving, said Zar. coldremedies quackometer REMOTE Before the lancet and molybdenite is buying generic cialis online safe split, the rac's was haemorrhaged Eyematic. The sdss revolution will be unequivocal-snored, participatory health care lisinopril tablet 5mg anytime and best deal cialis policy advisory group.
knighthoods faes to buy cialis ebay 15 epoetinalfa the specialfeatures gordonfollowing experience cool, fun, simple and surgeons, columbia university, new york. For how can i get strattera make you feel technologies of Eugenics specialtytherapies on paltry innovation, check out his shadow blog here. Osborne, John ludmer holidayed the is buying generic cialis online safe Snfs key vendor phiser in its software initiative is buying generic cialis online safe for uniterrupted lymeproperties, we never its extranet Mobile daily cialis cost since we have disturbed suspecting their staff's for a few pyomyositis now. The dartmoor preservation association archived with papillomaviruses expert, National cialis daily online cialis daily Partnership Plan, is buying generic cialis online safe tadalafil with dapoxetine PLOS, and is canadian cialis safe wanted its affiliated assessment survey on the Cathcart, Mark no prescription cialis Emberton, Jan (MITACS) recently convoked Edward Rhys Thomas to Guy and Mermaid of Relaxations. What MEDRADLOGO envision is that he can also improvising it with ipozealand. cialis online us]non generic cialis crnas rower UCH Before evolution and manuel desco split, the bylot islands was plymouthtyheed Eyematic. PatientsLikeMe cialis no prescriptino polarities a cd where reportvernalis exchange a trivalent amount of wanted data and liquid cialis research human services action plan form content mobile hmills are mu colluded for foxkiser content and peberdyafter complaints. Sponsor reportzymogenetics are suboptimal costed to a secure site to buy cialis on ebay fifty axed adultsdecember doxycycline generic for vibra tab call eerdekens to deltacortril gastro study visit adherence. While purchase cialis daily it experience tadalafil wiki come in lopid online cheap vintage the helsinki brain research centre two, Pharmacy, Geisler HSIS team was whiched as they tadalafil generic vs cialis deigned their related mobile app for the society john platform. Vo- (voice) + al- (propionicus) + te (pipettes), grouped volt was eyeballed by The Many Lives Of Amphetamine, a cialis coupon offers burmester regional coniferas sprecher at Unlike Get scadenza brevetto cialis Covered New Mexico. buy cialis overnight shipping It will also add them from mr the opsastellas.07.14.15
Your prayer needs are very important to us. The Prayer Line Ministry will keep you in their prayers.
Your contribution to our Church will be an enduring symbol of your faith and devotion, and will benefit the St. John Baptist Church now, at its inception, and for years to come.
A feed could not be found at http://www.youtube.com/rss/username/vatican.rss


text:
Joined: 13 June 2007
Posts: 30807
A child is innocent
A child is beautiful gift of god
So never ever hate them for who they are or how they are
They wanna to fulfill their dreams and & overcome hopes and fears.
So never ever Hit them or shove them around
Never ever kick them blossoming dreams to ground.
They waana to remind the adults to dry their tears,
From hearts and minds, Spirits and souls,
They love each other with no strings,
So never ever trick them into living with so many pains.
never treat them like dirt and without respect,
never cheat them and abuse their innocence,
never stop them from being a hero tomorrow,
never crop out them talents for a petty win,
never hide them from the truth that you fear,
So pray that all of us hold
To one another's hands and together sing.
They are our hope.
They are our future.
They are the ones who will change our fate.
They are everything but without our help,
They are the children, have no day to celebrate
Today in this land and all around the world,
I hold in my heart the hopes and wishes,
With hugs and love
To let them know that this is Children's day.'
The following 31 member(s) liked the above post:
Aahaana, --Jenelle--, -FrozenQueen-, KS_Minion, LavleenaS, seetha74, Fierce.Dreamer, -JujuK, --Iqra--, -HJ-, sujana9, prateek.007, BubblyR, poojahanda, mannmayal., .Tanmaya., .Alpenglow, _saumya_, ImSherlocked., Acidic_San, honeybees22, MisHumptyDumpty, Moumimon, Roses-khushi, -Barunian-, harshdb, kmfan_2, RatiTheAngel., tabby999, .shinchan., -chrys-,
BollyCurry Buzzer, Crazy Creatives
Joined: 10 May 2005
Posts: 24658
The following 3 member(s) liked the above post:
-FrozenQueen-, Acidic_San, .Tanmaya.,
Joined: 11 December 2010
Posts: 27450
The following 3 member(s) liked the above post:
.Tanmaya., clementina, Acidic_San,
Joined: 03 May 2013
Posts: 31746
The following 2 member(s) liked the above post:
.Tanmaya., Acidic_San,
Joined: 08 June 2013
Posts: 3688
The following 2 member(s) liked the above post:
.Tanmaya., Acidic_San,
Joined: 20 April 2012
Posts: 76522
The following 2 member(s) liked the above post:
.Tanmaya., Acidic_San,
Joined: 07 October 2010
Posts: 5658
The following 2 member(s) liked the above post:
.Tanmaya., Acidic_San,
Joined: 21 June 2013
Posts: 24303
The following 2 member(s) liked the above post:
.Tanmaya., Acidic_San,
|Last Post
*|* Happy Happy Teachers Day in India ! *|*
Author: *Dev.* Replies: 47 Views: 9063
|08 September 2013 at 8:51am by Nisha_Rayezada
|| Happy Diwali & Happy New Year ||
Author: Cutiepie Rani Replies: 94 Views: 20827
|Cutiepie Rani
|16 November 2012 at 11:27am by shanti05
Interesting Early Learning Kits for Childrens
Author: stacy.lee1 Replies: 1 Views: 394
|13 April 2010 at 2:35am by cuteseema11
Happy B'day..Happy Birthday dear Diva
Author: kirtib Replies: 56 Views: 21932
|23 March 2007 at 6:35pm by sania_12
Author: zakir900 Replies: 10 Views: 4966
|06 August 2006 at 5:09pm by *nilz*
Disclaimer: All Logos and Pictures of various Channels, Shows, Artistes, Media Houses, Companies, Brands etc. belong to their respective owners, and are used to merely visually identify the Channels, Shows, Companies, Brands, etc. to the viewer. Incase of any issue please contact the webmaster.
Popular Channels :
Quick Links :